VVOS Vivos Therapeutics Inc

$VVOS Huntsman suddenly publishing on LinkedIn after a long silence… 👀 Something is brewing. Things are starting to move. 🔥👇

$VVOS solid news. strong after hours volume. I See this being a multi day runner. A close today above. 20 would be a nice setup for tomorrow. $CIRC should see a continued uptrend tomorrow. $SLS glad i added on the pullback.. patients holding

$VVOS and are clearly insiders with large positions. Their write-up regarding chronic disease patient testing/aggregation is coming to pass with the news this week. Now they’re spamming the board with tons of bullish forecasts. Whether these lofty marks are possible or not, one thing’s for certain: they’re impossible if Huntsman’s still running the show. He’s been nothing but a failure as CEO of this company. Doesn’t take a medical expert to know that. So is this finally the turning point in this company’s history where adequate leadership is established? Or just another sky-high sales pitch and new market opportunity to be squandered under a lying, selfish, and incapable CEO Huntsman? your investment and market opportunity is not safe as long as Huntsman is employed at VVOS.

$VVOS Anyone that believes anything Kuntsman says at this point is either new here or just full of hopium. My shares in this company are dead to me and I’ll be voting no to everything at the coming shareholder meeting. If/when this 12k converts to another 80 million we will be near 500% dilution in 1 year and for years been hearing profitable next quarter, next quarter for literally 3 years now. Shame on me for believing this criminal! 🤦🏻‍♂️

$VVOS By 2030, ReBalU on Vivos's existing patient base alone adds $51.5M of sales, about 2.5 times Vivos's current annual revenue, and $20.6M of profit, about 80% of its trailing net loss. Because active patients build year on year, the stream is still growing in 2030. It needs no new clinics, no new patients and no national marketing. ReBalU through new clinics New clinics 2027 2028 2029 2030 Clinics open 3 6 9 12 Annual new patients in new clinics 36,000 72,000 108,000 144,000 New ReBalU patients 1,597 5,591 11,980 19,966 Active ReBalU patients 1,597 6,868 17,475 33,946 Sales $2.4M $10.3M $26.2M $50.9M Profit $1.0M $4.1M $10.5M $20.4M Each new clinic, once mature, enrolls about 2,662 new ReBalU patients a year. By 2030 the new clinics match the existing base, and together the two ReBalU streams reach 68,262 active patients, $102.4M of sales and $41.0M of profit. The ReBalU Primed Cell Test, national Primed Cell Test (diagnosed OSA market, 17.1 million) 2027 2028 2029 2030 Market share 1% 3% 6% 6% Patients tested 171,000 513,000 1,026,000 1,026,000 Sales to Vivos $171.0M $513.0M $1,026.0M $1,026.0M Profit to Vivos $51.3M $153.9M $307.8M $307.8M The test is the largest of the three streams because it reaches the national market, not only Vivos's own patients. Each tested patient retests quarterly, and Vivos's profit is taken at a conservative $300 a year. The table below shows the 2029 result, at 6% share, on each market size used. Market definition Size Tested at 6% Profit to Vivos Diagnosed OSA (base) 17,100,000 1,026,000 $307.8M All U.S. adults with OSA 80,600,000 4,836,000 $1,450.8M SOD channel base 500,000 30,000 $9.0M

$VVOS Let’s go, my friends! 🚀 Sooner or later, $VVOS is going to succeed. After all the suffering, we’re going to reach our goal. I can wait! 💪🔥

$VVOS very good news published yesterday that they took stake 11% and gains 50% stake in diagnostic test, should have been .30s

$VVOS I read the 8K. This cures the equity deficiency that was leading to delisting. Yes, a sweetheart deal. Now fire Huntsman, bring in a CEO the has scaled a business and get the price over $1. It's worth that with competent management, even with the dilution.

$VVOS For anyone interested in the new Vvos look at SOD2 enthusiasts recent post of a research report. It details explicitly what Vvos has just accomplished. Thr naked short is cooked! Streeterville finally loses big! I am long and will trade at will

$VVOS Vivos, you're testing my patience like my teenagers but I still love you and know you'll be okay one day....just hurry up and get there!

$VVOS part of me wants to put up the 6 grand and buy up that 48k road block order that sits there all night and pops up stopping momentum. But my fear is that it's just the tip of a iceberg. Fk it, I may do it, it's just a little bit of money.

$VVOS something to keep in mind (from the 8k dated Oct 19,2026) Sod has a potential max cap of ownership to 9.99% of OS. Full dilution of 80MM shares would require the count be much higher for their ownership to remain <10% (i.e., would need >800MM shares outstanding for Sod to convert the fully 80MM). The near term cap is 6MM and change (19.99% immediately), more would require shareholder approval. This is a mutual partnership, it would not be in Sod's or Vivos' best interest to dump all these shares at once. Sod is likely to sell up to the caps when it makes sense, but the deal was structured in a way to avoid, or at least not encourage, a full 80MM share convert and dump near term. Of course, this assumes I'm reading and coming to sound conclusions here, so correct me if any of this is wrong.

$VVOS I have said this many times I knew Kirk would get compliance. I think he making great decisions. This will be a stable company at some point with the stock price in the 20s. That is my opinion

$VVOS collaborates with SOD Sciences, taking an 11% stake and 50% of a pseudohypoxia patent and test in a $12M deal.

$VVOS fuckers. another news means, a new all time low today. why the fuck they did this now? market is killing all micro cap stocks

$VVOS I am thinking Kirk will take a backseat now and hire a CEO. I bet it will happen and the stock will fly !

$VVOS Vivos Therapeutics Regains Nasdaq Stockholders' Equity Compliance BENZINGA 6:04 AM ET 10/21/2026

$VVOS holding up pretty well. Been smacked down a couple times but has fought back everytime

$VVOS Should run nicely on the news. I think we might see +0.25. And I bought based on that.

$VVOS Vivos Therapeutics (Nasdaq: VVOS) Investment Research: What the SOD Sciences Transaction Adds to Vivos Sales and Earnings, 2027–2030 October 17, 2026. This report assumes the SOD Sciences transaction announced on Thursday, October 15, 2026 has closed. It looks only at what the transaction brings to Vivos's sales and earnings. It does not forecast Vivos's existing appliance and sleep‑center business. All sales and profit figures are Vivos's share: after the 50/50 split with SOD Sciences on ReBalU and the Primed Cell Test, and after SOD's 20% on Vivos devices sold through SOD's channels. Summary The transaction gives Vivos four new profit streams: the ReBalU Protocol sold to its own sleep‑center and cardiovascular‑clinic patients, the same protocol sold through new clinics Vivos adds, Vivos's 50% share of the national ReBalU Primed Cell Test, and Vivos's Vida appliance sold through SOD's channels, where Vivos keeps 80%. On the base case, by 2030 the four streams add $1,141.9M of sales and $361.6M of profit a year. ReBalU on Vivos's own 75,000 annual new patients alone adds $51.5M of sales and $20.6M of profit in 2030. With Vivos's existing business expected to reach breakeven by the first quarter of 2027, these additions are Vivos's base earnings. Contribution to Vivos 2027 2028 2029 2030 ReBalU, own 75,000 patients: sales $5.0M $16.5M $33.1M $51.5M ReBalU, own 75,000 patients: profit $2.0M $6.6M $13.3M $20.6M ReBalU, new clinics: sales $2.4M $10.3M $26.2M $50.9M ReBalU, new clinics: profit $1.0M $4.1M $10.5M $20.4M Primed Cell Test, national: sales $171.0M $513.0M $1,026.0M $1,026.0M Primed Cell Test, national: profit $51.3M $153.9M $307.8M $307.8M Vida through SOD channels: sales $44.5M $53.5M $62.5M $13.5M Vida through SOD channels: profit $42.3M $50.8M $59.4M $12.8M Total sales added $222.9M $593.3M $1,147.9M $1,141.9M Total profit added $96.5M $215.4M $390.9M $361.6M Profit added per fully diluted share $0.70 $1.57 $2.85 $2.64